



Supplementary Figure 1




Supplementary Figure 1: *Ex vivo* Stimulation with OKT3 and rIL-12 renders MAIT cells undetectable. PBMCs (n=12), tumor-free HMNCs (n=12), tumor-margin HMNCs (n=10) and tumor-infiltrating HMNCs (n=12) were isolated from CRLM patients. They were left untreated or exposed to a combination of anti-CD3 (clone OKT3) and rIL-12. Twenty-four hours later, cells were examined for their surface expression of CD3, Va7.2 and CD161. Note that while MAIT cells were undetectable in the vast majority (45 out of 46) of samples, conventional CD3⁺Va7.2⁻ T cells were either fully detectable (e.g., in patient 1), partially detectable (e.g., in patient 2) or completely undetectable (e.g., in patient 3).

Supplementary Figure 2



Supplementary Figure 2: Steady-state and inducible granzyme B expression by hepatic MAIT cells in CRLM patients. Tumor-free, tumor margin and tumor-infiltrating mononuclear cells were prepared from CRLM livers. Cells were left untreated or exposed to indicated stimuli followed, 24 hours later, by cytofluorimetric examination of intracellular granzyme B. Error bars represent SEM, and *p* values for several comparisons are shown.

Supplementary Figure 3



Supplementary Figure 3: CRLM patients with and without preoperative chemotherapy have similar MAIT cell frequencies in their blood circulation. Patients were divided into two groups, namely those receiving no chemotherapy and those treated with FOLFOX ± Avastin prior to liver resection surgery. MAIT cells were enumerated by flow cytometry. Each symbol represents an individual patient, and error bars represent SEM. NS: not significant (by unpaired student's *t*-test).

Supplementary Table 1. The IL-17A production capacity of hepatic MAIT cells in CRLM

	<i>Ex vivo</i> stimulation							
	None		rIL-12 + rIL-18		SEB		<i>Klebsiella</i> Lysate	
	Healthy Tissue	Tumor-infiltrating	Healthy Tissue	Tumor-infiltrating	Healthy Tissue	Tumor-infiltrating	Healthy Tissue	Tumor-infiltrating
Patient 1								
% IL-17A ⁺ MAIT cells	0.4	0.2	0.2	3.8	0.4	0.8	0.3	0.6
% IFN- γ ⁺ MAIT cells	1.6	0.3	37.9	0	17.4	0.4	11.3	0.8
Patient 2								
% IL-17A ⁺ MAIT cells	0.2	0.1	0.2	0.6	0.3	0.1	0.1	0.1
% IFN- γ ⁺ MAIT cells	2.5	0.2	56.3	30.0	39.4	29.6	53.6	28.7
Patient 3								
% IL-17A ⁺ MAIT cells	0.5	1.0	1.87	5.0	1.3	1.4	1.6	3.4